YD Bio Ltd — Investor Relations & Filings
Filings indexed
55
across all filing types
Latest filing
2026-03-26
Director's Dealing
Country
US
United States of America
Listing
US
YDES
YD Bio Ltd. is a biotechnology company that develops solutions for early cancer detection and regenerative medicine. The company's primary focus is on creating non-invasive, blood-based diagnostic tests for various cancers, including pancreatic and colorectal, through its OkaiDx™ testing portfolio. In parallel, YD Bio is advancing next-generation cell therapies, utilizing stem cell and exosome-based technologies. These therapeutic initiatives target applications in areas such as ophthalmology, with programs like its LSC Exosome Therapeutics. The company aims to improve patient lives by making its diagnostic and therapeutic innovations accessible.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 3 - YD Bio Ltd (0002011674) (Issuer) | 2026-03-26 | English | |
| 3 - YD Bio Ltd (0002011674) (Issuer) | 2026-03-18 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| 424B3 Filing | 2026-02-05 | English | |
| 6-K Filing | 2026-01-30 | English | |
| REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-21 | English |
Browse filings by year
3 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
10 filings
| |||||
| 33051985 | 3 - YD Bio Ltd (0002011674) (Issuer) | 2026-03-26 | English | ||
| 32976484 | 3 - YD Bio Ltd (0002011674) (Issuer) | 2026-03-18 | English | ||
| 32299107 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 32299365 | 424B3 Filing | 2026-02-05 | English | ||
| 32299164 | 6-K Filing | 2026-01-30 | English | ||
| 13691093 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-21 | English | ||
| 13691094 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-16 | English | ||
| 13691095 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-15 | English | ||
| 13691096 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-06 | English | ||
| 13691097 | REGISTRATION STATEMENT | 2026-01-02 | English | ||
|
2025
5 filings
| |||||
| 13691098 | Major Shareholding Notification 2025 | 2025-12-17 | English | ||
| 13691099 | PROSPECTUS | 2025-11-17 | English | ||
| 13691100 | REPORT OF FOREIGN PRIVATE ISSUER | 2025-11-17 | English | ||
| 13691101 | AMENDMENT NO. 1 TO FORM F-1 | 2025-10-24 | English | ||
| 13691102 | REPORT OF FOREIGN PRIVATE ISSUER | 2025-09-30 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
D.Western Therapeutics Institute, Inc.
Biotechnology firm developing drugs from a proprietary prot…
|
4576 | JP | Professional, scientific and te… |
|
Ecopia BioSciences Inc.
Developing novel anticancer agents and therapeutic solution…
|
EIA | CA | Professional, scientific and te… |
|
Ectin Research AB
Pharmaceutical company developing novel oncology treatments…
|
ECTIN B | SE | Professional, scientific and te… |
|
EdgeLab S.p.A.
Designs and manufactures marine and underwater solutions, i…
|
ELB | IT | Professional, scientific and te… |
|
Editas Medicine, Inc.
A clinical-stage genome editing company developing CRISPR m…
|
EDIT | US | Professional, scientific and te… |
|
EGF Theramed Health Corp.
Developing psychedelic drugs for mental health, diagnostic …
|
TMED | CA | Professional, scientific and te… |
|
Eikon Therapeutics, Inc.
Integrates live-cell imaging and computing to discover ther…
|
EIKN | US | Professional, scientific and te… |
|
Eledon Pharmaceuticals, Inc.
Clinical-stage biotech developing therapies for organ and a…
|
ELDN | US | Professional, scientific and te… |
|
Elicera Therapeutics AB
Clinical-stage immuno-oncology company developing cell and …
|
ELIC | SE | Professional, scientific and te… |
|
Elicio Therapeutics, Inc.
Clinical-stage biotech developing lymph node-targeted immun…
|
ELTX | US | Professional, scientific and te… |
YD Bio Ltd via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32250/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32250 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32250 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32250 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32250}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for YD Bio Ltd (id: 32250)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.